Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, double-blind, placebo-controlled, USA clinical study of inhaled nitric oxide (NO) using LungFit® PRO

X
Trial Profile

A Randomized, double-blind, placebo-controlled, USA clinical study of inhaled nitric oxide (NO) using LungFit® PRO

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Bronchiolitis; Community-acquired pneumonia; COVID 2019 infections; Pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Beyond Air
  • Most Recent Events

    • 12 Feb 2024 According to a Beyond Air media release, this study plan to include 50 patients at up to 10 sites. Top line data expected mid-year 2025 from VCAP study as trial is expected to extend over two seasons.
    • 03 Oct 2022 According to a Beyond Air media release, the company expect to initiate this trial in the fourth quarter of 2023, pending discussions with the FDA.
    • 18 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top